Management of pregnancies complicated by anti‐Fy<sup>a</sup> alloimmunization

Hughes, Laura; Rossi, Karen; Krugh, Dave; O’Shaughnessy, R.

doi:10.1111/j.1537-2995.2007.01408.x

Cited by 19 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fy a ) have been reported to induce severe HDFN that requires intrauterine blood transfusion. This, however, rarely occurs . In our study, we observed no cases of severe HDFN in 42 antigen‐positive fetuses but phototherapy was needed in 14% of the cases, compared to 4% in controls (no antibodies present or antigen‐negative fetus) .…”

Section: Clinical Relevance Of Different Red Cell Alloantibody Specifcontrasting

confidence: 39%

Haemolytic disease of the fetus and newborn

et al. 2015

View full text Add to dashboard Cite

Haemolytic Disease of the Fetus and Newborn (HDFN) is caused by maternal alloimmunization against red blood cell antigens. In severe cases, HDFN may lead to fetal anaemia with a risk for fetal death and to severe forms of neonatal hyperbilirubinaemia with a risk for kernicterus. Most severe cases are caused by anti-D, despite the introduction of antental and postnatal anti-D immunoglobulin prophylaxis. In general, red blood cell antibody screening programmes are aimed to detect maternal alloimmunization early in pregnancy to facilitate the identification of high-risk cases to timely start antenatal and postnatal treatment. In this review, an overview of the clinical relevance of red cell alloantibodies in relation to occurrence of HDFN and recent views on prevention, screening and treatment options of HDFN are provided.

show abstract

Section: Clinical Relevance Of Different Red Cell Alloantibody Specifcontrasting

confidence: 39%

Haemolytic disease of the fetus and newborn

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Clinically, both antibodies against Fy a or Fy b may result in hemolytic disease of the newborn and hemolytic transfusion reactions (1,10). Moreover, several recent studies have shown that FY*A and FY*B polymorphism is associated with serum concentration of monocyte chemoattractant protein-1 (MCP-1) and affects susceptibility to Plasmodium vivax malaria (11,12).…”

Section: Introductionmentioning

confidence: 99%

A New Method for Analyzing the Duffy Blood Group Genotype by TaqMan Minor Groove Binding Probes

Zhou

Liu

An³

et al. 2014

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The management of Rh-D blood type incompatible pregnancy is endorsed by the American College of Obstetricians and Gynecologists (ACOG) [2, 3]. The established treatment for prevention of sensitization during pregnancy is maternal administration of anti-D immunoglobulin [4, 5].…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment of Fetal Intraperitoneal Administration of Immunoglobulin in a Case of Fetal Hemolytic Anemia with 131,072-Fold Anti-E Alloimmunization

Yoshida

Matsuda²,

Hayata

et al. 2011

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

Object. We present here the case of severe fetal anemia caused by anti-E antibody positive, which showed a favorable course only with fetal intraperitoneal administration of immunoglobulin. Case. The mother was 31 years old, blood type B Rh : CCDee, gravida 1, with no history of transfusion. Anti-E antibody was detected in the maternal cross-match test at the 18th gestational week. In percutaneous umbilical blood sampling, the umbilical blood hemoglobin level was 9.1 g/dL and the result of the direct Coombs' test was positive at the 26th gestational week. Immunoglobulin injection into fetal abdominal cavity (IFAC) was administered a total 7 times. During the pregnancy, the indirect Coombs' test showed a 131,072-fold increase. Conclusion. In this case, IFAC to block the reticuloendothelial system Fc receptor was successful. This procedure is promising as one of the treatment options for blood group incompatible pregnancy.

show abstract

Management of pregnancies complicated by anti‐Fy^a alloimmunization

Abstract: Anti-Fy(a) has the potential to lead to significant fetal hemolysis. Management guidelines developed for D sensitization are appropriate for pregnancies complicated by anti-Fy(a) alloimmunization.

Cited by 19 publications

References 20 publications

Haemolytic disease of the fetus and newborn

Haemolytic disease of the fetus and newborn

A New Method for Analyzing the Duffy Blood Group Genotype by TaqMan Minor Groove Binding Probes

Successful Treatment of Fetal Intraperitoneal Administration of Immunoglobulin in a Case of Fetal Hemolytic Anemia with 131,072-Fold Anti-E Alloimmunization

Contact Info

Product

Resources

About

Management of pregnancies complicated by anti‐Fya alloimmunization

Abstract: Anti-Fy(a) has the potential to lead to significant fetal hemolysis. Management guidelines developed for D sensitization are appropriate for pregnancies complicated by anti-Fy(a) alloimmunization.

Cited by 19 publications

References 20 publications

Haemolytic disease of the fetus and newborn

Haemolytic disease of the fetus and newborn

A New Method for Analyzing the Duffy Blood Group Genotype by TaqMan Minor Groove Binding Probes

Successful Treatment of Fetal Intraperitoneal Administration of Immunoglobulin in a Case of Fetal Hemolytic Anemia with 131,072-Fold Anti-E Alloimmunization

Contact Info

Product

Resources

About

Management of pregnancies complicated by anti‐Fy^a alloimmunization